EA201991583A1 - METHOD FOR TREATING OR MAINTAINING METABOLIC DISORDERS USING PROTEINS BINDING A GASTRIC INHIBITOR PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP 1 AGONISTS - Google Patents

METHOD FOR TREATING OR MAINTAINING METABOLIC DISORDERS USING PROTEINS BINDING A GASTRIC INHIBITOR PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP 1 AGONISTS

Info

Publication number
EA201991583A1
EA201991583A1 EA201991583A EA201991583A EA201991583A1 EA 201991583 A1 EA201991583 A1 EA 201991583A1 EA 201991583 A EA201991583 A EA 201991583A EA 201991583 A EA201991583 A EA 201991583A EA 201991583 A1 EA201991583 A1 EA 201991583A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glp
combination
gipr
treating
agonists
Prior art date
Application number
EA201991583A
Other languages
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991583A1 publication Critical patent/EA201991583A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложены способы лечения метаболических заболеваний и нарушений, используя антигенсвязывающий белок, специфичный к полипептиду GIPR. В различных вариантах осуществления метаболическое заболевание или нарушение представляет собой диабет 2-го типа, ожирение, дислипидемию, повышенные уровни глюкозы, повышенные уровни инсулина или диабетическую нефропатию. В некоторых вариантах осуществления указанный антигенсвязывающий белок вводят в комбинации с агонистом рецептора GLP-1.Methods are proposed for treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide. In various embodiments, the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, or diabetic nephropathy. In some embodiments, said antigen binding protein is administered in combination with a GLP-1 receptor agonist.

EA201991583A 2016-11-10 2016-12-21 METHOD FOR TREATING OR MAINTAINING METABOLIC DISORDERS USING PROTEINS BINDING A GASTRIC INHIBITOR PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP 1 AGONISTS EA201991583A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662420415P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
EA201991583A1 true EA201991583A1 (en) 2019-11-29

Family

ID=68653630

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991583A EA201991583A1 (en) 2016-11-10 2016-12-21 METHOD FOR TREATING OR MAINTAINING METABOLIC DISORDERS USING PROTEINS BINDING A GASTRIC INHIBITOR PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP 1 AGONISTS

Country Status (1)

Country Link
EA (1) EA201991583A1 (en)

Similar Documents

Publication Publication Date Title
MX2022011277A (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists.
UY37568A (en) METHOD FOR TREATING OR IMPROVING METABOLIC DISORDERS THROUGH THE USE OF GLP-1 RECEPTOR AGONISTS CONJUGATED WITH PROTEINS UNIONING TO THE RECEPTOR OF THE GASTRIC INHIBITOR PEPTIDE (GIPR)
PH12019502603A1 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
MX2019015544A (en) Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins.
SV2017005548A (en) FUSION PROTEINS
EA201991345A1 (en) NEW COMPOUNDS AS PEPTIDE TRIPLE GLP1 / GLUCAGON / GIP RECEPTOR AGONISTS
EA201991583A1 (en) METHOD FOR TREATING OR MAINTAINING METABOLIC DISORDERS USING PROTEINS BINDING A GASTRIC INHIBITOR PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP 1 AGONISTS
MX2021007444A (en) Bispecific protein.
AR107190A1 (en) METHOD FOR TREATMENT OR RELIEF METABOLIC DISORDERS USING UNION PROTEINS FOR THE GASTRIC INHIBITOR PEPTHYDIC RECEIVER (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
Casellini et al. UNIQUE DIFFERENCES IN ADIPOKINES, MARKERS OF INFLAMMATION AND CIRCULATING GUT HORMONES AFTER BARIATRIC SURGERY BETWEEN OBESE NON DIABETIC, PREDIABETIC AND DIABETIC SUBJECTS
TH177202A (en) IL-22 polypeptide and IL-22 Fc protein fusion and method of use
Bellman et al. The effectiveness of GLP-1 analogues compared to DPP-4 inhibitors for beta cell function and diabetes related complications among adults with type 2 diabetes: a systematic review protocol
Druk et al. SITAGLIPTIN: CURRENT POSITIONS AND PROSPECTS FOR THERAPY OF TYPE 2 DIABETES MELLITUS